One patient with melanoma showed a complete response with total regression of lesions and remains free of disease from 32 months, another melanoma patient continues to show stable disease and months, and several others showed disease stability delayed disease progression. The only side effect was observed in the study. Temporary redness, swelling and itching at the injection site.. In a two-part, open-label cohort study, patients whose tumors expressed the immunogenic NY-ESO – 1 antigen, most with melanoma, received at least four monthly doses of recombinant vaccinia – NY-ESO-1 and recombinant fowlpox – NY-ESO – 1 vaccine alone alone and together in a prime-boost setting.
The Cancer Vaccine Collaborative earlier on studies testing several NY-ESO – 1 peptides and whole-body protein reported, and is currently considering , and bacterial, and bacterial vector-based NY-ESO-1 vaccines in particular, reported. CVC team in Melbourne last year on the efficacy of NY-ESO-1 peptide vaccine in combination with Iscomatrix used? adjuvant to prevent recurrence in melanoma patients appeared to be delayed. The court led the CVC in a randomized Phase II study – with the vaccine, which is now being put patients in Australia and the UK to more stable determine opening of vaccine effects on the entire course. Continue reading